BridgeBio Pharma BBIO Net product revenue — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's net product revenue — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's net product revenue — revenue?
- BridgeBio Pharma (BBIO) reported net product revenue — revenue of $180.6M in Q1 2026.
- How has BridgeBio Pharma's net product revenue — revenue changed year-over-year?
- BridgeBio Pharma's net product revenue — revenue increased by 391.6% year-over-year, from $36.74M to $180.6M.
- What is the long-term trend for BridgeBio Pharma's net product revenue — revenue?
- Over 2 years (2021 to 2025), BridgeBio Pharma's net product revenue — revenue has grown at a 877.5% compound annual growth rate (CAGR), from $3.79M to $362.4M.
- What does net product revenue — revenue mean?
- The total amount of money earned from selling the company's pharmaceutical products.
- How do you interpret net product revenue — revenue?
- An increase indicates successful commercial launch and market adoption of the company's therapeutic products, while a decrease may signal competitive pressure or lower-than-expected demand.
- How does net product revenue — revenue compare across companies?
- Comparable to product sales or net revenue reported by other commercial-stage biotechnology firms with rare disease or oncology portfolios.